US Pompe Disease Treatment Market

ID: MRFR/HC/11343-HCR 100 Pages Rahul Gotadki Last Updated: September 15, 2026
US Pompe Disease Treatment Market Research Report: By Treatment Type (Enzyme Replacement Therapy, Gene Therapy, Chaperone Therapy, Substrate Reduction Therapy), By Disease Severity (Infantile Pompe Disease, Late-Onset Pompe Disease, Classical Pompe Disease), By Route of Administration (Intravenous, Subcutaneous, Oral) and By Patient Age Group (Pediatric, Adult) - Growth & Industry Forecast 2025 To 2035
US Pompe Disease Treatment Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)3.33%
2024 Market Size$ 248.49 Million
2025 Market Size$ 256.76 Million
2035 Market Size$ 356.37 Million
Key Players
Sanofi
Genzyme
Amicus Therapeutics
Pfizer
Boehringer Ingelheim
Roche
Trends
  • Advancements in Enzyme Replacement Therapy
  • Emergence of Gene Therapy
  • Regulatory Support and Fast-Track Approvals
Opportunities
  • Increasing Prevalence of Pompe Disease
  • Investment in Research and Development
  • Enhanced Awareness and Education Initiatives
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Industrial Automation & Equipment, BY Type (USD Million)
      1. 4.1.1 Enzyme Replacement Therapy
      2. 4.1.2 Gene Therapy
      3. 4.1.3 Chaperone Therapy
      4. 4.1.4 Substrate Reduction Therapy
    2. 4.2 Industrial Automation & Equipment, BY Disease Severity (USD Million)
      1. 4.2.1 Infantile Pompe Disease
      2. 4.2.2 Late-Onset Pompe Disease
      3. 4.2.3 Classical Pompe Disease
    3. 4.3 Industrial Automation & Equipment, BY Route of Administration (USD Million)
      1. 4.3.1 Intravenous
      2. 4.3.2 Subcutaneous
      3. 4.3.3 Oral
    4. 4.4 Industrial Automation & Equipment, BY Patient Age Group (USD Million)
      1. 4.4.1 Pediatric
      2. 4.4.2 Adult
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Sanofi (FR)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Genzyme (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Amicus Therapeutics (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Pfizer (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Boehringer Ingelheim (DE)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Roche (CH)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 AstraZeneca (GB)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Eisai (JP)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE
    3. 6.3 US MARKET ANALYSIS BY DISEASE SEVERITY
    4. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    5. 6.5 US MARKET ANALYSIS BY PATIENT AGE GROUP
    6. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
    9. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
    11. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
    12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 (% SHARE)
    13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISEASE SEVERITY, 2024 (% SHARE)
    15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISEASE SEVERITY, 2024 TO 2035 (USD Million)
    16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
    18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY PATIENT AGE GROUP, 2024 (% SHARE)
    19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY DISEASE SEVERITY, 2025-2035 (USD Million)
      3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
      4. 7.2.4 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Pompe Disease Treatment Market Segmentation

US Pompe Disease Treatment Market By Type (USD Million, 2025-2035)

  • Enzyme Replacement Therapy
  • Gene Therapy
  • Chaperone Therapy
  • Substrate Reduction Therapy

US Pompe Disease Treatment Market By Disease Severity (USD Million, 2025-2035)

  • Infantile Pompe Disease
  • Late-Onset Pompe Disease
  • Classical Pompe Disease

US Pompe Disease Treatment Market By Route of Administration (USD Million, 2025-2035)

  • Intravenous
  • Subcutaneous
  • Oral

US Pompe Disease Treatment Market By Patient Age Group (USD Million, 2025-2035)

  • Pediatric
  • Adult

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.